New drug applications approved by US FDA as of 1 - 15 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Higher total fruit intake slightly but significantly reduces the risk of prostate cancer, reports a new prospective cohort study. No such associations have been established for vegetables or prostate cancer deaths.
Treatment with abiraterone acetate and prednisone for metastatic prostate cancer (mPC) in patients who responded poorly to initial androgen-deprivation therapy (ADT) showed encouraging results with favourable overall survival (OS) to historical controls, although the prespecified criteria for a positive result was not met , according to the S1014* trial.
Adding custirsen to the standard docetaxel-prednisone treatment to metastatic, castration-resistant prostate cancer does not significantly improve overall survival rates, according to the phase III, randomized, open-label SYNERGY trial.
Use of phosphodiesterase-5 (PDE5) inhibitors
following a first myocardial infarction (MI) may reduce the risk of
long-term adverse outcomes, including mortality and heart failure
hospitalization, in a dose-dependent fashion, according to a Swedish study.
The implant of a tibial nerve stimulator device for overactive bladder (OAB) appears to yield significant improvements in symptoms and quality of life (QoL) without inducing walking disturbances or pain at the implant site, according to a study.
Urinary stone disease is a common medical condition. Patients with acute stone disease may need admission to hospital for analgesia, intravenous hydration and, in some cases, decompression of the obstructed kidney. Those with non-acute disease should be followed up with serial imaging studies.